StockpollyBeta
Get App
Popularity #3,216
ENTA · NASDAQ · Biotechnology

Enanta Pharmaceuticals (ENTA)

Develops oral RSV antivirals and immunology drugs funded by AbbVie HCV royalties.

$12.08
vs last close−0.34 (−2.72%)

In millions of USD, except per-share figures

In millionsQ4 FY23Sep 2023Q1 FY24Dec 2023Q2 FY24Mar 2024Q3 FY24Jun 2024Q4 FY24Sep 2024Q1 FY25Dec 2024Q2 FY25Mar 2025Q3 FY25Jun 2025Q4 FY25Sep 2025Q1 FY26Dec 2025Q2 FY26Mar 2026Q3 FY26Jun 2026
Revenue191817181517151815191714
Cost of revenue000000000010
Gross profit191817181517151815191614
505350424441393734302832
Research & development363636293128282724211922
1417141314131110109109
General & administrative1417141314131110109109
Other expenses0000000000−10
Operating income−31−35−33−24−30−24−25−19−18−11−12−17
211111110−1−1−2
Interest income544333222220
Interest expense333232222334
Other non-operating income−5−4−4−3−3−3−2−2−2−2−2−2
Income before tax−30−34−32−23−29−23−24−18−19−12−13−19
Income tax expense−1−10000−100000
Net income from continuing operations−28−33−31−23−29−22−23−18−19−12−13−20
Net income−28−33−31−23−29−22−23−18−19−12−13−20
EPS, basic−$1.33−$1.58−$1.47−$1.07−$1.36−$1.05−$1.06−$0.86−$0.87−$0.42−$0.45−$0.67
EPS, diluted−$1.33−$1.58−$1.47−$1.07−$1.36−$1.05−$1.06−$0.86−$0.87−$0.42−$0.45−$0.67
Weighted average shares, basic212121212121212121292929
Weighted average shares, diluted212121212121212121292929
EBITDA−26−30−28−20−26−20−21−15−15−8−9−15
Depreciation & amortization111101111110
EBIT−26−31−29−21−27−21−22−17−16−9−10−15